Topic: Role of Liver Stem Cells in the Tumorigenic Progression of Liver Cancer

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 31 May 2020

Guest Editor(s)

  • Anne Corlu, PhD
    INSERM, Univ Rennes, INRA, Institut NuMeCAN (Nutrition Metabolisms and Cancer), F-35000 Rennes, France.

    Website | E-mail

  • Orlando Musso, MD, PhD
    INSERM, Univ Rennes, INRA, Institut NuMeCAN (Nutrition Metabolisms and Cancer), F-35000 Rennes, France.

    Website | E-mail

Special Issue Introduction

Hepatocellular carcinoma (HCC) is the leading cause of death in patients with severe liver fibrosis. Over 80% of HCCs arise in a background of liver fibrosis resulting from chronic viral infections, alcohol abuse, as well as exposure to aflatoxin B, genetic diseases and metabolic syndrome. The only potentially curative treatment for a minority of selected cases is liver transplantation. Recently, encouraging therapeutic results have been reported with protocols that apply one or more of the following methods: partial hepatectomy, tumor ablation, chemoembolization, selective internal radiation therapy; as well as systemic approaches with multikinase inhibitors and targeting of anti-tumor immunity. Despite this wealth of therapeutic strategies, treatment resistance and hence cancer progression result from co-evolution of an ecosystem composed of cancer cells themselves and their microenvironment. Evolving interactions within this ecosystem progressively select the fittest cancer stem cells. Stemness displays a diversity of phenotypes involving, but not limited to, cell plasticity, metabolic adaptations, drug detoxification, immune escape and quiescence, which converge to generate pluripotency. Cancer progression through the emergence of pluripotency ultimately fosters the survival of the fittest cancer cells. In this special issue, the diversity of phenotypes and pathways leading to stemness in hepatocellular carcinomas is reviewed.


Tania Roskams   KU Leuven– University Hospital Leuven, Belgium
Kun Guo   Dalian Med University, China
Giuseppe Carruba   Unit of Research & Internationalization, Italy
Raymond Wu   University of Southern Calif Keck Sch Med, USA
German L Velez-Reyes   Masonic Cancer Center University of Minnesota Minneapolis MN, USA

Submission Deadline

31 May 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 May 2020
Contacts: Delphine Wong, Assistant Editor,

Published Articles

This special issue is now open for submission.